AB011. SOH24AB_147. Radiotherapy for muscle invasive bladder cancer (MIBC): friend or foe?—A 10-year review of radiotherapy use for MIBC in the southeast of Ireland
Urology Session

AB011. SOH24AB_147. Radiotherapy for muscle invasive bladder cancer (MIBC): friend or foe?—A 10-year review of radiotherapy use for MIBC in the southeast of Ireland

Amanda Troy, Kevin Keane, Orla Cullivan, Irfan Afridi, Mohamed Khalid, Keith Gerraghty, Mohammed Aboelmagd, Padraig Daly, John Keane

Department of Urology, University Hospital Waterford, Waterford, Ireland

Background: Trimodality therapy (TMT) combines transurethral resection of bladder tumour (TURBT), radiotherapy (RT), and chemotherapy. European Association of Urology guidelines contain a “strong” recommendation that TMT can “be offered as an alternative to select patients, for whom radical cystectomy (RC) is not an option”. Five-year survival ranges 36–74%, with salvage cystectomy rates 10–30%.

Methods: We retrospectively reviewed patients treated with RT for muscle invasive bladder cancer (MIBC) in the southeast of Ireland between February 2013–February 2023. Data were collected from medical records and RT databases.

Results: We identified 72 patients (55 males,17 females) with a median age of 76 years. Radical radiotherapy (radRT) was performed with curative intent in 32 patients and palliative RT in 32 patients. Indications for radRT included: refused surgery/wanted bladder preservation (n=19, 59%), unfit for cystectomy (n=15, 47%), adjuvant radRT for positive margins following RC (n=2, 6%). Concurrent/neoadjuvant chemotherapy was given in 31 (97% of patients had TMT), surveillance cystoscopies were performed in 20 (62.5%), and surveillance imaging was performed in 29 (90.6%). Salvage cystectomy rate was 6.2% (n=2). The 2- and 5-year survival was 50% and 42% respectively in the radRT cohort. And, 6.2% (n=2) patients had radRT between 2013–2019 due to desire for bladder sparing treatment but this number increased to 17 (53%) in 2020–2023; 91% of radRT was performed between 2020–2023 versus 9% (n=3) in 2013–2019.

Conclusions: RadRT is being increasingly used for treatment of MIBC, with increasing numbers requesting bladder preserving treatment. Implementing a TMT approach requires close collaboration between different specialties and strict patient adherence to surveillance. Our study highlights salvage cystectomy, cystoscopic and imaging surveillance rates lower than other published series.

Keywords: Bladder cancer; muscle invasive; radiotherapy (RT); trimodality; urology

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-24-ab011
Cite this abstract as: Troy A, Keane K, Cullivan O, Afridi I, Khalid M, Gerraghty K, Aboelmagd M, Daly P, Keane J. AB011. SOH24AB_147. Radiotherapy for muscle invasive bladder cancer (MIBC): friend or foe?—A 10-year review of radiotherapy use for MIBC in the southeast of Ireland. Mesentery Peritoneum 2024;8:AB011.

Article Options

Download Citation

Share